{"title":"揭示ACTL6A在癌症中的致癌作用和预后价值：一项系统综述和荟萃分析。","authors":"Soumya Patil, Raushan Kumar Chaudhary, Prakash Patil, Praveenkumar Shetty, Vijith Vittal Shetty, Krishna Sharan, Uday Venkat Mateti","doi":"10.1080/1354750X.2025.2556170","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Actin-like protein 6 A (ACTL6A), a subunit of SWItch/sucrose non-fermentable (SWI/SNF) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumourigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance.</p><p><strong>Methods: </strong>A systematic search in PubMed, Scopus and Web of Science was conducted from inception to 31 December 2024, using the keywords 'ACTL6A' and 'Cancer'. Studies investigating ACTL6A's role in cancer and those reporting hazard ratios (HRs) for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively.</p><p><strong>Results: </strong>A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumuorigenesis, invasion and metastasis <i>via</i> HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (<i>n</i> = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (<i>p</i> = 0.001), larger tumour size (<i>p</i> < 0.01) and higher tumour grade (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-13"},"PeriodicalIF":1.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis.\",\"authors\":\"Soumya Patil, Raushan Kumar Chaudhary, Prakash Patil, Praveenkumar Shetty, Vijith Vittal Shetty, Krishna Sharan, Uday Venkat Mateti\",\"doi\":\"10.1080/1354750X.2025.2556170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Actin-like protein 6 A (ACTL6A), a subunit of SWItch/sucrose non-fermentable (SWI/SNF) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumourigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance.</p><p><strong>Methods: </strong>A systematic search in PubMed, Scopus and Web of Science was conducted from inception to 31 December 2024, using the keywords 'ACTL6A' and 'Cancer'. Studies investigating ACTL6A's role in cancer and those reporting hazard ratios (HRs) for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively.</p><p><strong>Results: </strong>A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumuorigenesis, invasion and metastasis <i>via</i> HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (<i>n</i> = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (<i>p</i> = 0.001), larger tumour size (<i>p</i> < 0.01) and higher tumour grade (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.</p>\",\"PeriodicalId\":8921,\"journal\":{\"name\":\"Biomarkers\",\"volume\":\" \",\"pages\":\"1-13\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1354750X.2025.2556170\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2025.2556170","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis.
Background: Actin-like protein 6 A (ACTL6A), a subunit of SWItch/sucrose non-fermentable (SWI/SNF) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumourigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance.
Methods: A systematic search in PubMed, Scopus and Web of Science was conducted from inception to 31 December 2024, using the keywords 'ACTL6A' and 'Cancer'. Studies investigating ACTL6A's role in cancer and those reporting hazard ratios (HRs) for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively.
Results: A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumuorigenesis, invasion and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumour size (p < 0.01) and higher tumour grade (p = 0.002).
Conclusion: ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.
期刊介绍：
The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.
Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged:
• Biomarkers of disease
• Biomarkers of exposure
• Biomarkers of response
• Biomarkers of susceptibility
Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
